Shen and Hsu's startup Xilis present MicroOrganoSphere technology for cancer drug screening

xilis logo
GCB News

Shen and Hsu's startup Xilis present MicroOrganoSphere technology for cancer drug screening

Xilis, Inc., a pioneering company developing its MicroOrganoSphereTM (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, announced today the presentation of data on the company’s proprietary MOS technology. Data were presented at the 2021 European Society for Medical Oncology (ESMO) Congress in an oral presentation and two poster presentations.

“There is a significant unmet need for a patient-derived microtumor platform that captures the entire microenvironment and heterogeneity of the originating tumor tissue for accurate, rapid and high-throughput therapeutic profiling,” said Xiling Shen, PhD, Founder and Chief Executive Officer of Xilis. “In these three presentations, we provide evidence that our MOS technology retains the same characteristics as patient samples and has the capability to quickly evaluate cancer drug response. Our platform can support pharmaceutical companies in accelerating drug discovery and development and is being developed to help clinicians make more informed treatment decisions.”

Read more on Business Wire

Related News

stack of books

Research Roundup: September 2021

Here are summaries of a selection of the papers published by GCB faculty in September 2021:

view
elephant, whale tale, turtle, zebras

Hilmar Lapp to help establish new field of 'Imageomics'

Hilmar Lapp is part of an interdisciplinary, multi-institutional collaboration led by Ohio State that will establish a new field of study

view